A longitudinal study on circulating miR-21 as a therapeutic effect marker in head and neck squamous cell carcinoma. (11th April 2019)

• Record Type: Journal Article
• Authors: Ishinaga, Hajime; He, Feng; Hou, Bo; Shah, SaidAhmad; Murata, Mariko; Takeuchi, Kazuhiko
• Is Part Of: Carcinogenesis. Volume 40:Number 9(2019)
• Page Start: 1070
• Page End: 1076
• Publication Date: 2019-04-11
• Subjects: Carcinogenesis -- Periodicals; Cancer -- Genetic aspects -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Periodicals; 616.994071
• DOI: 10.1093/carcin/bgz075
• Languages: English
• ISSNs: 0143-3334

Abstract

Abstract: The aim of the study is to investigate plasma miR-21 for a possible therapeutic effect determination marker in head and neck squamous cell carcinoma (HNSCC). Plasma samples are obtained from 86 HNSCC patients and 29 non-cancer volunteers who had been treated at Mie University Hospital between May 2015 and December 2016, and plasma miR-21 expression was measured using real-time quantitative reverse transcription polymerase chain reaction. In addition, plasma miR-21 level of advanced HNSCC patients including 22 non-recurrent cases and 11 recurrent cases before and after treatment was analyzed using a longitudinal design. Plasma miR-21 expression in 86 HNSCC patients was obviously higher than in 29 control patients ( P < 0.0001). The area under the curve (AUC) for plasma miR-21 was 0.756 (95% confidence interval: 0.661–0.851). Furthermore, our longitudinal study of plasma miR-21 showed that the expression level of plasma miR-21 was significantly reduced at the time point of 2 months after treatment in case of no recurrence. On the other hand, plasma miR-21 was not decreased after treatment in case of 10 patients who had developed recurrences during the follow-up period. This study may provide new insights into the role of plasma miR-21 as a biomarker for HNSCC, and plasma miR-21 would be useful for early detection of tumor recurrence after operation or chemoradiotherapy. Abstract : Longitudinal study showed that plasma miR-21 was significantly reduced at 2 months after treatment in HNSCC of no recurrence. On the other hand, plasma miR-21 was not decreased after treatment with patients who had developed recurrences during the follow-up period.